Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg + Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Asthma
Conditions
Asthma
Trial Timeline
Apr 15, 2022 → Aug 29, 2023
NCT ID
NCT05322707About Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg + Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol + Placebo
Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg + Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol + Placebo is a phase 3 stage product being developed by Cipla for Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT05322707. Target conditions include Asthma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05322707 | Phase 3 | Completed |
Competing Products
20 competing products in Asthma
Other Products from Cipla
Generic HAART Triomune : d4T, 3TC, NVP + Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABVApproved
85
Insulin Lispro-aabc + Insulin GlargineApproved
85
CBT124 + EU-sourced Avastin® + Carboplatin + PaclitaxelPhase 3
77
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) + Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1 + Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2 + PlaceboPhase 3
77
90 mcg Reference Product + 180 mcg Reference Product + 90 mcg Test Product + PlaceboPhase 3
77